1. 123P IMpower010: Exploratory overall survival (OS) with adjuvant atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression. (December 2022) Authors: Rittmeyer, A.; Felip, E.; Altorki, N.K.; Vallieres, E.; Zhou, C.; Martinez-Marti, A.; Csoszi, T.; Reck, M.; Teixeira, M.E.; Deng, Y.; Huang, M.; McNally, V.A.; Bennett, E.; Gitlitz, B.J.; Srivastava, M.; Wakelee, H. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Issue 3 (September 2015) Authors: Vansteenkiste, J.; Fehrenbacher, L.; Spira, A.I.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; Braiteh, F.; Yi, J.; He, P.; Kowanetz, M.; Waterkamp, D.; Ballinger, M.; Chen, D.S.; Sandler, A.; Rittmeyer, A. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S716 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. (January 2019) Authors: von Pawel, J.; Bordoni, R.; Satouchi, M.; Fehrenbacher, L.; Cobo, M.; Han, J.Y.; Hida, T.; Moro-Sibilot, D.; Conkling, P.; Gandara, D.R.; Rittmeyer, A.; Gandhi, M.; Yu, W.; Matheny, C.; Patel, H.; Sandler, A.; Ballinger, M.; Kowanetz, M.; Park, K. Journal: European journal of cancer Issue: Volume 107(2019) Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗